News & Updates

Show Multimedia Only

Bax24 data boost baxdrostat potential for resistant HTN

21 Apr 2026 by

The results of the phase III Bax24 trial underpin the efficacy of baxdrostat, a selective aldosterone synthase inhibitor (ASI), for the treatment of uncontrolled or resistant hypertension (HTN).

Bax24 data boost baxdrostat potential for resistant HTN

21 Apr 2026

Study highlights potential link between VOCs and CVD, mortality

20 Apr 2026

Exposure to volatile organic compounds (VOCs) may be associated with increased risks of cardiovascular disease (CVD) and CVD death, as suggested in a systematic review and meta-analysis.

Study highlights potential link between VOCs and CVD, mortality

20 Apr 2026

Ultrasound-facilitated, catheter-directed thrombolysis beneficial in intermediate-risk PE

18 Apr 2026 by

In the treatment of patients with acute, intermediate-risk pulmonary embolism (PE), administering ultrasound-facilitated, catheter-directed thrombolysis (USCDT) on top of anticoagulation results in better short-term outcomes compared with anticoagulation alone, as shown in the multinational, adaptive-design, open-label HI-PEITHO trial.

Ultrasound-facilitated, catheter-directed thrombolysis beneficial in intermediate-risk PE

18 Apr 2026

Transcatheter ViV may be a safe short-term option to repeat MVR

18 Apr 2026 by

The transcatheter valve-in-valve (ViV) procedure appears to be a safe option for select patients requiring repeat surgery after failed mitral bioprostheses, according to findings from the randomized controlled SURViV trial presented at ACC.26. However, it is still early days for the ViV approach.

Transcatheter ViV may be a safe short-term option to repeat MVR

18 Apr 2026

Methotrexate may lower CV risk in psoriasis patients

17 Apr 2026 by

Patients with psoriasis who are treated with methotrexate (MTX) show a reduced incidence of metabolic syndrome and better cardiometabolic profiles, according to a study presented at AAD 2026.

Methotrexate may lower CV risk in psoriasis patients

17 Apr 2026

SURPASS-CVOT: Tirzepatide better than dulaglutide for cardiorenal outcomes

17 Apr 2026 by

Treatment with tirzepatide, a dual GLP-1* and GIP** agonist, significantly improves cardiovascular and renal outcomes in patients with diabetes and atherosclerotic cardiovascular disease (ASCVD) compared with dulaglutide, according to a post hoc analysis of the SURPASS-CVOT trial presented at ACC.26.

SURPASS-CVOT: Tirzepatide better than dulaglutide for cardiorenal outcomes

17 Apr 2026

SMART-DECISION: Stable post-MI patients can be safely taken off beta-blockers after 1 year

16 Apr 2026 by

Stopping beta-blockers after a year of regular use does not appear to increase the risk of adverse clinical outcomes in myocardial infarction (MI) survivors without evidence of left ventricular systolic dysfunction or heart failure (HF), as shown in the SMART-DECISION trial.

SMART-DECISION: Stable post-MI patients can be safely taken off beta-blockers after 1 year

16 Apr 2026

MetS risk higher in children with primary hypertension

16 Apr 2026

Children with hypertension, particularly those with primary hypertension, are vulnerable to developing metabolic syndrome (MetS), reveals a study.

MetS risk higher in children with primary hypertension

16 Apr 2026

ICLAD predicts poor vascular outcomes after ischaemic stroke

16 Apr 2026 by

The presence of intracranial large artery disease (ICLAD) is associated with poor composite vascular outcomes, myocardial infarction (MI), and vascular death, but not recurrence, in patients with acute ischaemic stroke, suggests a Singapore study.

ICLAD predicts poor vascular outcomes after ischaemic stroke

16 Apr 2026

Novel lithotripsy device fares well in PINNACLE-I trial

16 Apr 2026 by

The PINNACLE-I trial shows the feasibility, safety, and efficacy of LithiX, a novel Hertz contact intravascular lithotripsy (HC-IVL) device, for the treatment of calcified coronary artery lesions.

Novel lithotripsy device fares well in PINNACLE-I trial

16 Apr 2026

News & Updates

Showing Cardiology articles

Showing

Specialty:

Bax24 data boost baxdrostat potential for resistant HTN

Bax24 data boost baxdrostat potential for resistant HTN

Study highlights potential link between VOCs and CVD, mortality

Study highlights potential link between VOCs and CVD, mortality

Ultrasound-facilitated, catheter-directed thrombolysis beneficial in intermediate-risk PE

Ultrasound-facilitated, catheter-directed thrombolysis beneficial in intermediate-risk PE

Transcatheter ViV may be a safe short-term option to repeat MVR

Transcatheter ViV may be a safe short-term option to repeat MVR

Methotrexate may lower CV risk in psoriasis patients

Methotrexate may lower CV risk in psoriasis patients

SURPASS-CVOT: Tirzepatide better than dulaglutide for cardiorenal outcomes

SURPASS-CVOT: Tirzepatide better than dulaglutide for cardiorenal outcomes

SMART-DECISION: Stable post-MI patients can be safely taken off beta-blockers after 1 year

SMART-DECISION: Stable post-MI patients can be safely taken off beta-blockers after 1 year

MetS risk higher in children with primary hypertension

MetS risk higher in children with primary hypertension

ICLAD predicts poor vascular outcomes after ischaemic stroke

ICLAD predicts poor vascular outcomes after ischaemic stroke

Novel lithotripsy device fares well in PINNACLE-I trial

Novel lithotripsy device fares well in PINNACLE-I trial